Michael S Oh

6PUBLICATIONS
25CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Nov 01, 2026
A CCL21 gene-modified dendritic cell vaccine combined with pembrolizumab in advanced non-small cell lung cancer: a phase I trial.

|Mar 28, 2025
Tumor Heterogeneity and the Immune Response in Non-Small Cell Lung Cancer: Emerging Insights and Implications for Immunotherapy.

Michael S Oh, Jensen Abascal, Austin K Rennels

|Nov 19, 2024
Characteristics of a CCL21 Gene-Modified Dendritic Cell Vaccine Utilized for a Clinical Trial in Non-Small Cell Lung Cancer.

Michael S Oh, Camelia Dumitras, Ramin Salehi-Rad

|May 07, 2020
Early Assessment of Molecular Progression and Response by Whole-genome Circulating Tumor DNA in Advanced Solid Tumors.

Andrew A Davis, Wade T Iams, David Chan

|Mar 03, 2019
Mutations in DNA repair genes are associated with increased neoantigen burden and a distinct immunophenotype in lung squamous cell carcinoma.

Young Kwang Chae, Jonathan F Anker, Michael S Oh

|Dec 16, 2017
Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions.

Young Kwang Chae, Michael S Oh, Francis J Giles

Pageof 1

Frequent Collaborators

3 joint publications

Bin Liu

2 joint publications

Ramin Salehi-Rad

2 joint publications

Linh M Tran

2 joint publications

Steven M Dubinett